Search

Your search keyword '"Elimova, E."' showing total 163 results
Start Over Author "Elimova, E."
163 results on '"Elimova, E."'

1. 1202TiP Evolution of the tumor immune microenvironment in hepatocellular carcinoma (HCC) and non-squamous non-small cell lung cancer (NSCLC) with liver metastases treated with atezolizumab and bevacizumab (INTEGRATE)

Author

Sacher, A., primary, Lau, S., additional, Allen, M., additional, Corke, L., additional, Makarem, M., additional, Chen, E., additional, Jang, R.W-J., additional, Elimova, E., additional, Grant, R., additional, Shepherd, F.A., additional, Bradbury, P., additional, Eng, L., additional, Rogalla, P., additional, Liu, G., additional, Tsao, M-S., additional, Leighl, N., additional, Garonce-Hediger, R., additional, Wang, B., additional, Ohashi, P., additional, and Knox, J., additional

Published
2022
Full Text
View/download PDF

4. P-26 HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)

Author

Tabernero, J., primary, Elimova, E., additional, Ku, G., additional, Shitara, K., additional, Shen, L., additional, Liu, T., additional, Lin, X., additional, Boyken, L., additional, Li, H., additional, Grim, J., additional, and Ajani, J., additional

Published
2022
Full Text
View/download PDF

5. 1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)

Author

Ku, G., primary, Elimova, E., additional, Denlinger, C.S., additional, Mehta, R., additional, Lee, K-W., additional, Iqbal, S., additional, Kang, Y-K., additional, Oh, D-Y., additional, Rha, S.Y., additional, Kim, Y.H., additional, Seol, Y.M., additional, Mwatha, T., additional, Grim, J., additional, and Ajani, J.A., additional

Published
2021
Full Text
View/download PDF

7. 1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577

Author

Moehler, M., primary, Ajani, J.A., additional, Kuzdzal, J., additional, Zander, T., additional, Van Cutsem, E., additional, Piessen, G., additional, Mendez, G., additional, Feliciano, J., additional, Motoyama, S., additional, Lièvre, A., additional, Uronis, H., additional, Elimova, E., additional, Grootscholten, C., additional, Geboes, K., additional, Zhang, J., additional, Soleymani, S., additional, Lei, M., additional, Kondo, K., additional, Cleary, J., additional, and Kelly, R.J., additional

Published
2021
Full Text
View/download PDF

8. 1406P Survival outcomes in older adults with metastatic gastric and esophageal carcinoma receiving palliative chemotherapy

Author

Allen, M.J., primary, Espin-Garcia, O., additional, Suzuki, C., additional, Panov, E., additional, Ma, L., additional, Yvonne, B., additional, Jang, R., additional, Chen, E., additional, Darling, G., additional, Yeung, J., additional, Swallow, C., additional, Brar, S., additional, Kalimuthu, S., additional, Wong, R., additional, Veit-Haibach, P., additional, and Elimova, E., additional

Published
2021
Full Text
View/download PDF

9. 886P Circulating tumor DNA kinetics in recurrent/metastatic head & neck squamous cell cancer (R/M HNSCC) patients

Author

Taylor, K., primary, Zou, J., additional, Burgener, J., additional, Zhao, E., additional, Torti, D., additional, Oliva, M., additional, Spreafico, A., additional, Hansen, A.R., additional, Jang, R., additional, McDade, S.S., additional, Coyle, V.M., additional, Lawler, M., additional, Elimova, E., additional, Bratman, S.V., additional, and Siu, L.L., additional

Published
2021
Full Text
View/download PDF

10. LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study

Author

Janjigian, Y.Y., primary, Ajani, J.A., additional, Moehler, M., additional, Garrido, M., additional, Gallardo, C., additional, Shen, L., additional, Yamaguchi, K., additional, Wyrwicz, L., additional, Skoczylas, T., additional, Bragagnoli, A., additional, Liu, T., additional, Tehfe, M., additional, Elimova, E., additional, Li, M., additional, Poulart, V., additional, Lei, M., additional, Kondo, K., additional, and Shitara, K., additional

Published
2021
Full Text
View/download PDF

11. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577

Author

Moehler, M., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lievre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Zhang, J., Soleymani, S., Lei, M., Kondo, K., Cleary, J., Kelly, R. J., Moehler, M., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lievre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Zhang, J., Soleymani, S., Lei, M., Kondo, K., Cleary, J., and Kelly, R. J.

Published
2021

13. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma

Author

Jiang, DM, Suzuki, C, Espin-Garcia, O, Lim, CH, Ma, LX, Sun, P, Sim, HW, Natori, A, Chan, BA, Moignard, S, Chen, EX, Liu, G, Swallow, CJ, Darling, GE, Wong, R, Jang, RW, Elimova, E, Jiang, DM, Suzuki, C, Espin-Garcia, O, Lim, CH, Ma, LX, Sun, P, Sim, HW, Natori, A, Chan, BA, Moignard, S, Chen, EX, Liu, G, Swallow, CJ, Darling, GE, Wong, R, Jang, RW, and Elimova, E

Abstract

Background: The goal of surveillance testing is to enable curative salvage therapy through early disease detection, however supporting evidence in gastroesophageal adenocarcinoma is limited. We evaluated frequency of successful salvage therapy and outcomes in patients who underwent surveillance. Methods: A single-site, retrospective cohort study was conducted to identify all patients who received curative resection for gastroesophageal adenocarcinoma. Surveillance testing were those investigations not triggered by abnormal symptoms, physical examination, or blood tests. Successful salvage therapy was any potentially curative therapy for disease recurrence which resulted in postrecurrence disease-free survival ≥2 years. Time-to-event data were analyzed using the Kaplan-Meier method and log rank tests. Results: Between 2011 and 2016, 210 consecutive patients were reviewed. Esophageal (14%), gastroesophageal junction (40%), and gastric adenocarcinomas (45%) were treated with surgery alone (29%) or multimodality therapy (71%). Adjuvant therapy was administered in 35%. At median follow-up of 38.3 months, 5-year overall survival (OS) rate was 56%. Among 97 recurrences, 53% were surveillance-detected, and 46% were symptomatic. None was detected by surveillance endoscopy. Median time-to-recurrence (TTR) was 14.8 months. Recurrences included locoregional only (4%), distant (86%), and both (10%). Salvage therapy was attempted in 15 patients, 4 were successful. Compared to symptomatic recurrences, patients with surveillance-detected recurrences had longer median OS (36.2 vs 23.7 months, P =.004) and postrecurrence survival (PRS, 16.5 vs 4.6 months, P <.001), but similar TTR (16.2 vs 13.3 months, P =.40) and duration of palliative chemotherapy (3.9 vs 3.3 months, P =.64). Conclusions: Among patients surveyed, 96% of recurrences were distant, and salvage therapy was successful in only 1.9% of patients. Longer OS in patients with surveillance-detected compared to symptomatic recu

Published
2020

14. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study

Author

Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J. L., Motoyama, S., Lievre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Zhang, J., Zhu, L., Lei, M., Kondo, K., Cleary, J. M., Moehler, M., Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J. L., Motoyama, S., Lievre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Zhang, J., Zhu, L., Lei, M., Kondo, K., Cleary, J. M., and Moehler, M.

Published
2020

16. O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577

Author

Kelly, R., Moehler, M., Ajani, J., Yao, J., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Yang, Y., Zhang, J., Novosiadly, R., Cleary, J., and Lei, M.

Published
2023
Full Text
View/download PDF

17. 1464P Asian-ethnicity related differences among patients with metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma

Author

Honório, M.X., primary, Suzuki, C., additional, Espin-Garcia, O., additional, Allen, M.J., additional, Ma, L., additional, Almugbel, F.A., additional, Gonzalez, I. Lyra, additional, Darling, G., additional, Yeung, J.C-W., additional, Chen, E., additional, Kalimuthu, S., additional, Wong, R., additional, Veit-Haibach, P., additional, Jang, R., additional, and Elimova, E., additional

Published
2020
Full Text
View/download PDF

18. LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study

Author

Kelly, R.J., primary, Ajani, J.A., additional, Kuzdzal, J., additional, Zander, T., additional, Van Cutsem, E., additional, Piessen, G., additional, Mendez, G., additional, Feliciano, J.L., additional, Motoyama, S., additional, Lièvre, A., additional, Uronis, H., additional, Elimova, E., additional, Grootscholten, C., additional, Geboes, K., additional, Zhang, J., additional, Zhu, L., additional, Lei, M., additional, Kondo, K., additional, Cleary, J.M., additional, and Moehler, M., additional

Published
2020
Full Text
View/download PDF

19. 1460P Impact of sites of metastatic dissemination on survival in advanced gastroesophageal adenocarcinoma

Author

Wang, X., primary, Espin-Garcia, O., additional, Suzuki, C., additional, Bach, Y., additional, Jiang, D., additional, Ma, L.X., additional, Allen, M.J., additional, Honório, M.X., additional, Chen, E., additional, Darling, G., additional, Yeung, J.C-W., additional, Wong, R., additional, Veit-Haibach, P., additional, Sangeetha, K., additional, Jang, R.W-J., additional, and Elimova, E., additional

Published
2020
Full Text
View/download PDF

25. Medical management of gastric cancer: a 2017 update

Author

Charalampakis, N. Economopoulou, P. Kotsantis, I. Tolia, M. Schizas, D. Liakakos, T. Elimova, E. Ajani, J.A. Psyrri, A.

Abstract

Gastric cancer remains a considerable health burden throughout the world. The Cancer Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with data not ready to change treatment strategy yet. A multimodality approach to therapy is the cornerstone of screening, diagnosing, staging, treating and supporting patients with gastric cancer. The evidence-based approach to localized gastric cancer (>cT1b) is to use an either preoperative or postoperative strategy to maximize the benefit of surgery. The focus of future research is to optimize chemotherapy regimens, determine the role of radiation therapy and investigate the effect of treatment timing. In metastatic gastric cancer, biologic therapies have been introduced targeting markers shown to be prognostic. The results of ongoing randomized controlled phase 3 trials using targeted and immunotherapy agents, either in combination or alone, have the potential to alter the current treatment landscape of advanced gastric cancer. © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Published
2018

26. Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

Author

Oh, D.-Y., primary, Hamilton, E., additional, Hanna, D., additional, Beeram, M., additional, Lee, K.-W., additional, Kang, Y.-K., additional, Chaves, J., additional, Lee, J.-Y., additional, Goodwin, R., additional, Vaklavas, C., additional, Rha, S.-Y., additional, Elimova, E., additional, Mayordomo, J., additional, Ferrario, C., additional, Cobleigh, M., additional, Fortenberry, A., additional, Rowse, G., additional, Gray, T., additional, Lai, R., additional, and Meric Bernstam, F., additional

Published
2019
Full Text
View/download PDF

27. Genomic characterisation of locally advanced pancreatic adenocarcinoma

Author

Picardo, S., primary, O’Kane, G.M., additional, Fischer, S., additional, Zhang, A., additional, Denroche, R., additional, Jang, G., additional, Dodd, A., additional, Grant, R.C., additional, Gruenwald, B., additional, Moura, S., additional, Wang, Y., additional, Elimova, E., additional, Prince, R., additional, Zogopoulos, G., additional, Notta, F., additional, Wilson, J., additional, Gallinger, S., additional, and Knox, J.J., additional

Published
2019
Full Text
View/download PDF

28. Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

Author

Meric-Bernstam, F., primary, Hanna, D., additional, Beeram, M., additional, Lee, K.-W., additional, Kang, Y.-K., additional, Chaves, J., additional, Lee, J., additional, Goodwin, R., additional, Vaklavas, C., additional, Oh, D.-Y., additional, Rha, S.Y., additional, Elimova, E., additional, Mayordomo, J., additional, Ferrario, C., additional, Cobleigh, M.A., additional, Fortenberry, A., additional, Rowse, G., additional, Gray, T., additional, Lai, R., additional, and Hamilton, E., additional

Published
2019
Full Text
View/download PDF

30. Impact of sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)

Author

Fares, A.F., primary, Taylor, K., additional, Bajwa, J., additional, Dong, G., additional, Araujo, D.V., additional, Hueniken, K., additional, Patel, D., additional, Chen, E.X., additional, Knox, J.J., additional, Jang, R W-J, additional, Wong, R., additional, Darling, G., additional, Elimova, E., additional, Xu, W., additional, Rozenberg, D., additional, Liu, G., additional, and Mcinnis, M., additional

Published
2019
Full Text
View/download PDF

31. Outcomes by Treatment Modality in Elderly Patients with Localized Gastric and Esophageal Cancer

Author

Natori, A., primary, Chan, B.A., additional, Sim, H.W., additional, Ma, L., additional, Yokom, D.W., additional, Chen, E., additional, Liu, G., additional, Darling, G., additional, Swallow, C., additional, Brar, S., additional, Brierley, J., additional, Ringash, J., additional, Wong, R., additional, Kim, J., additional, Rogalla, P., additional, Hafezi-Bakhtiari, S., additional, Conner, J., additional, Knox, J., additional, Elimova, E., additional, and Jang, R.W., additional

Published
2018
Full Text
View/download PDF

33. Molecular profiling of PDAC and response to chemotherapy: An update from the COMPASS trial

Author

O’Kane, G.M., primary, Fischer, S., additional, Denroche, R.E., additional, Jang, G.H., additional, Zhang, A., additional, Dodd, A., additional, Albaba, H., additional, Moura, S., additional, Holter, S., additional, Aung, K., additional, Grant, R.C., additional, Krzyzanowski, P., additional, Elimova, E., additional, Dhani, N., additional, Hedley, D., additional, Notta, F., additional, Wilson, J.M., additional, Gallinger, S., additional, and Knox, J.J., additional

Published
2018
Full Text
View/download PDF

41. 2254 Initial standardized uptake value (iSUV) of positron emission tomography (PET) influences prognosis of patients with localized gastric adenocarcinoma treated preoperatively

Author

Charalampakis, N., primary, Xiao, L., additional, Elimova, E., additional, Wadhwa, R., additional, Shiozaki, H., additional, Shimodaira, Y., additional, Blum, M., additional, Planjery, V., additional, Rogers, J., additional, Matamoros, A., additional, Sagebiel, T., additional, Das, P., additional, Lee, J., additional, Bhutani, M., additional, Weston, B., additional, Estrella, J., additional, Badgwell, B., additional, and Ajani, J., additional

Published
2015
Full Text
View/download PDF

42. 2264 Metastatic gastroesophageal adenocarcinoma patients treated with systemic therapy followed by local therapy: A nomogram associated with long-term survivors

Author

Shiozaki, H., primary, Elimova, E., additional, Slack, R., additional, Chen, H.C., additional, Planjery, V., additional, Charalampakis, N., additional, Wadhwa, R., additional, Shimodaira, Y., additional, Skinner, H., additional, Lee, J., additional, Weston, B., additional, Bhutani, M., additional, Blum, M., additional, Rogers, J., additional, Maru, D., additional, Estrella, J., additional, Das, P., additional, Hofstetter, W., additional, Badgwell, B., additional, and Ajani, J., additional

Published
2015
Full Text
View/download PDF

43. 2246 Relapse patterns in patients with localized gastric adenocarcinoma (LGAC) treated with combined modality therapy: Implications for surveillance strategies

Author

Elimova, E., primary, Slack, R., additional, Chen, H.C., additional, Planjery, V., additional, Shiozaki, H., additional, Shimodaira, Y., additional, Charalampaki, N., additional, Wadhwa, R., additional, Estrella, J.S., additional, Sagebiel, T., additional, Lee, J.H., additional, Weston, B., additional, Bhutani, M., additional, Blum, M., additional, Matamoros, A., additional, Das, P., additional, Mansfield, P., additional, Badgwell, B., additional, and Ajani, J., additional

Published
2015
Full Text
View/download PDF

45. 44P BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy.

Author

O'Kane, G.M., Spratlin, J., Oh, D-Y., Rha, S.Y., McWhirter, E., Elimova, E., Kavan, P., Choi, M.K., Kim, D., Goodwin, R.A., Hecht, J.R., Koo, D-H., Halani, K., McAllister, R., Jones, M., Snow, M.D., Lemmerick, Y., Spera, G., and Pankovich, J.

Subjects
*ANTINEOPLASTIC combined chemotherapy protocols
Published
2024
Full Text
View/download PDF

46. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Author

Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Litvre, A., Uronis, H., Elimova, E., Grootscholten, C., Geboes, K., Zafar, S., Snow, S., Ko, A. H., Feeney, K., Schenker, M., and Kocon, P.

Subjects
*ESOPHAGOGASTRIC junction, *CHEMORADIOTHERAPY, *PROGRESSION-free survival, *DISEASE relapse, *CONFIDENCE intervals
Abstract

Background: No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.Methods: We conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with esophageal or gastroesophageal junction cancer. Adults with resected (R0) stage II or III esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy and had residual pathological disease were randomly assigned in a 2:1 ratio to receive nivolumab (at a dose of 240 mg every 2 weeks for 16 weeks, followed by nivolumab at a dose of 480 mg every 4 weeks) or matching placebo. The maximum duration of the trial intervention period was 1 year. The primary end point was disease-free survival.Results: The median follow-up was 24.4 months. Among the 532 patients who received nivolumab, the median disease-free survival was 22.4 months (95% confidence interval [CI], 16.6 to 34.0), as compared with 11.0 months (95% CI, 8.3 to 14.3) among the 262 patients who received placebo (hazard ratio for disease recurrence or death, 0.69; 96.4% CI, 0.56 to 0.86; P<0.001). Disease-free survival favored nivolumab across multiple prespecified subgroups. Grade 3 or 4 adverse events that were considered by the investigators to be related to the active drug or placebo occurred in 71 of 532 patients (13%) in the nivolumab group and 15 of 260 patients (6%) in the placebo group. The trial regimen was discontinued because of adverse events related to the active drug or placebo in 9% of the patients in the nivolumab group and 3% of those in the placebo group.Conclusions: Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma

Author

Josep Tabernero, Lin Shen, Elena Elimova, Geoffrey Ku, Tianshu Liu, Kohei Shitara, Xiao Lin, Lisa Boyken, Huiyan Li, Jonathan Grim, Jaffer Ajani, Institut Català de la Salut, [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, IOB-Quiron, Barcelona, Spain. [Shen L] Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, China. [Elimova E] Princess Margaret Cancer Centre, Toronto, Ontario, Canada. [Ku G] Memorial Sloan Kettering Cancer Center, New York, USA. [Liu T] National Cancer Center Hospital, Kashiwa, Chiba, Japan. [Shitara K] Zhongshan Hospital, Shanghai, China, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Cancer Research, Esophageal Neoplasms, Receptor, ErbB-2, Programmed Cell Death 1 Receptor, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias del esófago [ENFERMEDADES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Antineoplastic Agents, Adenocarcinoma, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Antibodies, Monoclonal, Humanized, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Esophageal Neoplasms [DISEASES], Esòfag - Càncer - Tractament, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales [COMPUESTOS QUÍMICOS Y DROGAS], Anticossos monoclonals - Ús terapèutic, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma [DISEASES], neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::carcinoma::adenocarcinoma [ENFERMEDADES], Antibodies, Monoclonal, General Medicine, Trastuzumab, Adenocarcinoma - Tractament, Oncology, Esophagogastric Junction, Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal [CHEMICALS AND DRUGS]
Abstract

HER2-positive gastroesophageal adenocarcinomas (GEAs) are common cancers with high mortality and the treatment options for advanced/metastatic disease are limited. Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA. Preliminary data suggest that dual targeting of the HER2 and PD-1 pathways could further improve upon the results achieved with targeting either pathway alone. Here, we describe the design of HERIZON-GEA-01, a global, randomized, open-label, active-comparator, Phase III study to evaluate and compare the efficacy and safety of zanidatamab plus chemotherapy with or without tislelizumab to the standard of care (trastuzumab plus chemotherapy) as first-line treatment for patients with advanced/metastatic HER2-positive GEAs.HERIZON-GEA-01: A phase III study of zanidatamab + chemotherapy ± tislelizumab for first-line treatment of advanced or metastatic #HER2-positive gastroesophageal adenocarcinoma (GEA). Clinicaltrials.gov: NCT05152147. #gastriccancer #stomachcancer @ZymeworksInc @BeiGeneGlobal

Published
2022

48. Outcomes in older adults with metastatic esophageal and gastric carcinoma treated with palliative chemotherapy.

Author

Wang X, Allen MJ, Espin-Garcia O, Suzuiki C, Bach Y, Panov E, Ma LX, Jang RW, Chen EX, Darling GE, Yeung J, Swallow CJ, Brar SS, Kalimuthu S, Wong R, Veit-Haibach P, and Elimova E

Subjects
Humans, Aged, Male, Female, Retrospective Studies, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Treatment Outcome, Age Factors, Neoplasm Metastasis, Esophageal Neoplasms drug therapy, Esophageal Neoplasms pathology, Esophageal Neoplasms mortality, Palliative Care methods, Stomach Neoplasms drug therapy, Stomach Neoplasms pathology, Stomach Neoplasms mortality
Abstract

Background: The incidence of esophageal and gastric carcinoma (GEC) in elderly patients is increasing, yet patients ≥75 years have historically been underrepresented in clinical trials. We sought to investigate palliative chemotherapy administration patterns and survival outcomes in older adults., Materials and Methods: A retrospective analysis identified patients aged 65-74 (young-old) and ≥75 years (older-old) diagnosed with advanced GEC. Patient and tumor characteristics were recorded, with descriptive analysis, time-to-event data analysis using Kaplan-Meier curves and multivariate Cox proportional hazards regression analysis performed., Results: One hundred and ninety-eight "young-old" and 109 'older-old' patients were identified. Patient characteristics were similar between groups except for Charlson Co-morbidity Index (CCI), with lower co-morbidities in the "young-old" compared to "older-old" cohort (P < .001; CCI = 0 in 103 (52%) "young-old" vs 31 (28%) "older-old"). The primary diagnosis in both groups was adenocarcinoma. 119 (60%) "young-old" and 25 (23%) "older-old" patients received chemotherapy (P < .001). Performance status was the primary explanation for chemotherapy non-receipt in both cohorts; age was the explanation in 21 (25%) "older-old" patients and none in the "young-old" patients. PFS for first-line systemic therapy in "young-old" patients was 6.4 (95% CI 5.9-7.6) versus 7.5 months (95% CI 5.1-11.3) in "older-old" patients (P = .69) whilst respective OS was 12.3 (95% CI 10.1-15.5) and 10.4 months (95% CI 9.0-14.6) (P = .0816). Toxicity prompted chemotherapy cessation in 17 (15%) "young-old" and 3 (13%) "older-old" patients (P = .97). Multivariate analysis identified CCI and ECOG performance status as predictive for PFS and OS, respectively. No causative relationship was identified with other variables., Conclusion: Our study of real-world older-adults show that significant number of "older-old" patients with GEC do not receive chemotherapy. Among "older-old" adults who do receive systemic therapy, outcomes are comparable; this underscores the importance of geriatric assessment-guided care and suggests that age alone should not be a barrier to receipt of chemotherapy in patients with advanced GEC., (© The Author(s) 2024. Published by Oxford University Press.)

Published
2024
Full Text
View/download PDF

49. Vascular Resection for Pancreas Cancer - 10-year Experience from a Single High Volume-center.

Author

Henault D, Kunde H, Zatzman C, Bevacqua D, Arshinoff D, Cleary SP, Dawson LA, Elimova E, Grant R, Hosni A, Jang RW, Knox JJ, Mesci A, Moore M, Moulton CE, Reichman TW, Shwaartz C, Tsang ES, McGilvray ID, and Gallinger S

Abstract

Objective Background: Combined pancreatic and vascular resections are increasingly performed for pancreatic ductal adenocarcinoma (PDAC). We evaluated the outcomes after pancreatectomy with non-vascular resection (NVR), venous resection (VR), and arterial resection (AR)., Methods: Retrospective review (2011-2023) of 715 PDAC patients treated with curative-intent surgery. Associations among clinicopathological data, perioperative therapy, time to recurrence (TTR), and overall survival (OS) were evaluated., Results: Initial staging revealed 533 resectable, 98 borderline, and 84 locally advanced PDAC cases. Pancreaticoduodenectomy was the most common procedure (n=467). NVR was performed in 351 (58.2%) patients, VR in 181 (30.0%), and AR in 70 (11.8%). The median TTR and OS did not significantly differ according to the initial staging or type of pancreas resection. Median TTR and OS were significantly shorter for VR (14.5 and 22.7 mo) compared to NVR (18.6 and 30.5 mo, P<0.001) and AR (20.6 and 30.9 mo, P=0.004 and P=0.017). Chemotherapy or chemoradiation significantly prolonged TTR (20.1 vs. 10.2 mo, P<0.001 and 25.3 vs. 16.4 mo, P<0.001) and OS (31.5 vs. 17.2 mo, P<0.001 and 35.5 vs. 27.5 mo, P=0.030). AR was associated with higher 90-day mortality rates. In the multivariable analysis, vascular resection was not associated with OS. Perioperative therapy, pathological N0 status, and absence of perineural invasion were the key predictors of longer TTR and OS., Conclusions: Pancreatectomy with AR was not associated with worse oncological outcomes when controlling for perioperative therapy. However, AR was associated with higher 90-day mortality rates. Patient selection is crucial when performing AR in patients with PDAC., Competing Interests: Conflict of Interest declaration: The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

50. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.

Author

Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Karamouzis M, Bruges R, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, Wang R, Lei M, Chen C, Nathani R, and Shitara K

Subjects
Humans, Male, Follow-Up Studies, Female, Aged, Middle Aged, Progression-Free Survival, Adult, Esophageal Neoplasms drug therapy, Esophageal Neoplasms pathology, Esophageal Neoplasms mortality, Adenocarcinoma drug therapy, Adenocarcinoma mortality, Adenocarcinoma pathology, Stomach Neoplasms drug therapy, Stomach Neoplasms pathology, Stomach Neoplasms mortality, Nivolumab therapeutic use, Nivolumab adverse effects, Nivolumab administration & dosage, Esophagogastric Junction pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects
Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We report 3-year efficacy and safety results from the phase III CheckMate 649 trial. Patients with previously untreated advanced or metastatic gastroesophageal adenocarcinoma were randomly assigned to nivolumab plus chemotherapy or chemotherapy. Primary end points were overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) in patients whose tumors expressed PD-L1 combined positive score (CPS) ≥5. With 36.2-month minimum follow-up, for patients with PD-L1 CPS ≥5, the OS hazard ratio (HR) for nivolumab plus chemotherapy versus chemotherapy was 0.70 (95% CI, 0.61 to 0.81); 21% versus 10% of patients were alive at 36 months, respectively; the PFS HR was 0.70 (95% CI, 0.60 to 0.81); 36-month PFS rates were 13% versus 8%, respectively. The objective response rate (ORR) per BICR was 60% (95% CI, 55 to 65) with nivolumab plus chemotherapy versus 45% (95% CI, 40 to 50) with chemotherapy; median duration of response was 9.6 months (95% CI, 8.2 to 12.4) versus 7.0 months (95% CI, 5.6 to 7.9), respectively. Nivolumab plus chemotherapy also continued to show improvement in OS, PFS, and ORR versus chemotherapy in the overall population. Adding nivolumab to chemotherapy maintained clinically meaningful long-term survival benefit versus chemotherapy alone, with an acceptable safety profile, supporting the continued use of nivolumab plus chemotherapy as standard first-line treatment for advanced gastroesophageal adenocarcinoma.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results